101 : CAFC Alert

For Biotech, “Method of Preparation” Claims May Survive §101

| April 15, 2020

Illumina, Inc. v. Ariosa Diagnostics, Inc.

March 17, 2020

Lourie, Moore, and Reyna (Opinion by Lourie; Dissent by Reyna)

Summary

In a patent infringement litigation between the same parties that were involved in the earlier case, Ariosa Diagnostics, Inc. v. Sequenom, Inc., 788 F.3d 1371 (Fed. Cir. 2015) (diagnostic patent deemed patent ineligible under 35 U.S.C. §101), the United States Court of Appeals for the Federal Circuit (“Federal Circuit”) found the claimed “method of preparation” of a fraction of cell-free fetal DNA (“cff-DNA”) enriched in fetal DNA to be patent eligible, reversing the district court’s grant of summary judgment of patent ineligibility.  A dissent by J. Reyna (author of the earlier Ariosa decision) asserts that there is nothing new and useful in the claims, other than the discovery that cff-DNA tends to be shorter than cell-free maternal DNA, and that use of known laboratory techniques and commercially available testing kits to isolate the naturally occurring shorter cff-DNA does not make the claims patent eligible.

Details

Illumina and Sequenom (collectively, “Illumina”) appealed a summary judgment ruling of patent ineligibility by the United States District Court for the Northern District of California.  The two patents at issue, USP 9,580,751 (the ‘751 patent) and USP 9,738,931 (the ‘931 patent), are unrelated to the diagnostic patent held ineligible in the 2015 Ariosa decision.  While the earlier litigated patent claimed a method for detecting the small fraction of cff-DNA in the plasma and serum of a pregnant woman that were previously discarded as medical waste, the present ‘751 and ‘931 patents claim methods for preparing a fraction of cff-DNA that is enriched in fetal DNA.  A problem with maternal plasma is that it was difficult, if not impossible, to determine fetal genetic markers (e.g., for certain diseases) because the proportion of circulatory extracellular fetal DNA in maternal plasma was tiny as compared to the majority of it (>90%) being circulatory extracellular maternal DNA. The inventor’s “surprising” discovery was that the majority of circulatory extracellular fetal DNA has a relatively small size of approximately 500 base pairs or less, as compared to the larger circulatory extracellular maternal DNA.  With this discovery, they developed the following claimed methods for preparing a DNA fraction that separated fetal DNA from maternal DNA from the maternal plasma and serum, to create a DNA fraction enriched with fetal DNA.

‘931 Patent:

1.         A method for preparing a deoxyribonucleic acid (DNA) fraction from a pregnant human female useful for analyzing a genetic locus involved in a fetal chromosomal aberration, comprising:

            (a) extracting DNA from a substantially cell-free sample of blood plasma or blood serum of a pregnant human female to obtain extracellular circulatory fetal and maternal DNA fragments;

            (b) producing a fraction of the DNA extracted in (a) by:

                        (i) size discrimination of extracellular circulatory DNA fragments, and

                        (ii) selectively removing the DNA fragments greater than approximately 500 base pairs, wherein the DNA fraction after (b) comprises a plurality of genetic loci of the extracellular circulatory fetal and maternal DNA; and

            (c) analyzing a genetic locus in the fraction of DNA produced in (b).

‘751 Patent:

1.         A method, comprising:

            (a) extracting DNA comprising maternal and fetal DNA fragments from a substantially cell-free sample of blood plasma or blood serum of a pregnant human female;

            (b) producing a fraction of the DNA extracted in (a) by:

                        (i) size discrimination of extracellular circulatory fetal and maternal DNA fragments, and

                        (ii) selectively removing the DNA fragments greater than approximately 300 base pairs, wherein the DNA fraction after (b) comprises extracellular circulatory fetal and maternal DNA fragments of approximately 300 base pairs and less and a plurality of genetic loci of the extracellular circulatory fetal and maternal DNA fragments; and

            (c) analyzing DNA fragments in the fraction of DNA produced in (b).

The Federal Circuit had consistently found diagnostic claims patent ineligible (as directed to natural phenomenon) (Athena Diagnostics, Inc. v. Mayo Collaborative Servs., LLC, 927 F.3d 1333 (Fed. Cir. 2019); Athena Diagnostics, Inc. v. Mayo Collaborative Servs., LLC, 915 F.3d 743 (Fed. Cir. 2019); Cleveland Clinic Found. v. True Health Diagnostics LLC, 859 F.3d 1352 (Fed. Cir. 2017)).  In contrast, the Federal Circuit had also held that method of treatment claims are patent eligible (Endo Pharm. Inc. v. Teva Pharm. USA, Inc., 919 F.3d 1347 (Fed. Cir. 2019); Natural Alternative Int’l, Inc. v. Creative Compounds, LLC, 918 F.3d 1338 (Fed. Cir. 2019); and Vanda Pharm. Inc. v. West-Ward Pharm. Int’l Ltd., 887 F.3d 1117 (Fed. Cir. 2018)).  However, this is not a diagnostic case, nor a method of treatment case.  This is a method of preparation case – which the Federal Circuit found to be patent eligible.

The natural phenomenon at issue is that cell-free fetal DNA tends to be shorter than cell-free maternal DNA in the mother’s bloodstream.  However, under the Alice/Mayo Step 1, the Federal Circuit held that these claims are not directed to a natural phenomenon.  Instead, the claims are directed to a method that utilizes that phenomenon.  The claimed method recites specific process steps – size discrimination and selective removal of DNA fragments above a specified size threshold.  These process steps change the composition of the normal maternal plasma or serum, creating a fetal DNA enriched mixture having a higher percentage of cff-DNA fraction different from the naturally occurring fraction in the normal mother’s blood.  “Thus, the process achieves more than simply observing that fetal DNA is shorter than maternal DNA or detecting the presence of that phenomenon.”

In distinguishing the earlier Ariosa case, the Federal Circuit stated, “the claims do not merely cover a method for detecting whether a cell-free DNA fragment is fetal or maternal based on its size.” 

In distinguishing the Supreme Court decision in Association for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013), the Federal Circuit noted that the “Supreme Court in Myriad expressly declined to extend its holding to method claims reciting a process used to isolate DNA” and that “in Myriad, the claims were ineligible because they covered a gene rather than a process for isolating it.”  Here, the method “claims do not cover cell-free fetal DNA itself but rather a process for selective removal of non-fetal DNA to enrich a mixture in fetal DNA.”  This is the opposite of Myriad.

As for whether the techniques for size discrimination and selective removal of DNA fragments were well-known and conventional, those considerations are relevant to the Alice/Mayo Step 2 analysis, or to 102/103 issues – not for Alice/Mayo Step 1.  The majority concluded patent eligibility under Step 1 and did not proceed to Step 2.

J. Reyna’s dissent focused on the claims being directed to a natural phenomenon because the “only claimed advance is the discovery of that natural phenomenon.”  In particular, referring to a “string of cases reciting process claims” since 2016, the “directed to” inquiry under Alice/Mayo Step 1 asks “whether the ‘claimed advance’ of the patent ‘improves upon a technological process or is merely an ineligible concept.’” citing Athena, 915 F.3d at 750 and Genetic Techs., 818 F.3d at 1375.  “Here, the claimed advance is merely the inventors’ ‘surprising[]’ discovery of a natural phenomenon – that cff-DNA tends to be shorter than cell-free maternal DNA in a mother’s bloodstream.”  J. Reyna criticizes the majority for ignoring the “claimed advance” inquiry altogether.

Under the claimed advance inquiry, one looks to the written description.  Here, the written description identifies the use of well-known and commercially available tools/kits to perform the claimed method.  Checking for 300 and 500 base pairs using commercially available DNA size markers and kits does not constitute any “advance.”  There is no improvement in the underlying DNA processing technology, but for checking the natural phenomenon of sizes indicative of cff-DNA.

J. Reyna also criticized the majority’s “change in the composition of the mixture” justification.  “A process that merely changes the composition of a sample of naturally occurring substances, without altering the naturally occurring substances themselves, is not patent eligible.”  Here, one begins and ends with the same naturally occurring substances – cell-free fetal DNA and cell free maternal DNA.  There is no creation or alteration of any genetic information encoded in the cff-DNA.  Therefore, the claims are directed to a natural phenomenon under Alice/Mayo Step 1. 

J. Reyna also found no inventive concept under Alice/Mayo Step 2.

Take Away

  • Until there is an en banc rehearing or a Supreme Court review of this case, this case is an example of a patent eligible method of preparation claim.
  • For defendants, the “claimed advance” inquiry could help sink a claimed method under Alice/Mayo Step 1. 

The Patent-Ineligibility trend continues to be infectious…

| October 29, 2018

Roche Molecular Systems, Inc. v. Cepheid

October 9, 2018

Before O’Malley, Reyna and Hughes. Opinion by Reyna. Concurring opinion by O’Malley.

Summary:

The contended patent, U.S. Patent No. 5,643,723 (‘723 patent), owned by Roche is directed to methods for detecting the pathogenic bacterium Mycobacterium tuberculosis (MTB). Prior to the priority date, the general methods of detection were slow (could take three to eight weeks), and they had limitations in that they could not identify if a patient has an antibiotic-resistant strain. The standard of care at the time was treatment with the antibiotic rifampin. However, outbreaks resulted due to delays in diagnosing and reporting of the rifampin-resistant tuberculosis. In 1994, rpoB became a prime candidate for studying rifampin resistance in MTB.

The inventors of the ‘723 patent sequenced the rpoB gene in MTB and discovered that that the rpoB gene in MTB contains eleven “position-specific” “signature nucleotides” (i.e., naturally occurring single nucleotide mutations) that are only present in MTB but not in other bacteria. Based on these eleven MTB-specific signature nucleotides, the Roche inventors devised a diagnostic test that could (1) identify whether or not a biological sample contains MTB, and (2) if MTB is present, predict whether that MTB is a strain that is resistant to rifampin treatment.


Read More/続きを読む

Alice: ‘This is impossible’ (Alice in Wonderland 2010): Alice (Corp. Pty. Ltd. v. CLS Bank Int’l,), aid’s in striking yet another blow against the pursuit of diagnostic test method

| June 26, 2017

Cleveland Clinic Foundation v. True Health Diagnostics LLC

June 16, 2017

Before Lourie, Reyna and Wallach.  Opinion by Reyna.

Summary:

The CAFC affirmed the invalidly of method claims in three diagnostic test patents held by Cleveland Clinic Foundation (hereon – Cleveland Clinic), and further affirmed that True Health Diagnostics LLC (hereon – True Health) was not liable for contributory or induced infringement of a fourth patent directed to methods of treating patients diagnosed by the diagnostic tests.

This CAFC decision strikes another blow against the patent eligibility of diagnostic methods, while further highlighting the difficulty of enforcing method treatments based on such diagnostic tests (i.e., personalized medicine).


Read More/続きを読む

Surviving Alice Gone Wild

| November 26, 2014

Before the Supreme Court’s decision in Alice Corp. v CLS Bank Int’l [1], Judge Moore said “this case is the death of hundreds of thousands of patents, including all business method, financial system, and software patents as well as many computer implemented and telecommunications patents.”[2] This concern is premised on about twenty years of patent practice grounded in the en banc 1994 Federal Circuit decision in In re Alappat which previously established the “special purpose computer” justification for patent eligibility under 35 USC §101 for computer-implemented inventions.[3]  The Alice decision essentially eliminated the “special purpose computer” bright line rule as applied generally to computer-implemented inventions.  The new Mayo 2-part §101 test for computer-implemented inventions is, however, fraught with issues from the lack of guidance on how to properly apply it.  Some strategic arguments for surviving a §101 attack are presented in this article, as well as a new way to address what is “significantly more.”


Read More/続きを読む

The Alice in Wonderland En Banc Decision by the Federal Circuit in CLS Bank v. Alice

| May 13, 2013

CLS Bank v. Alice Corporation (en banc)

May 10, 2013

After the Federal Circuit issued its en banc decision on May 10, 2013 in CLS Bank v. Alice Corp, the patent owner Alice Corp must be feeling like Alice in Alice in Wonderland, bewildered and frightened by the fantastical situation in which they find themselves:

(1) “bewildered” because an equally divided Federal Circuit affirmed the district court’s holding that Alice’s claimed system to tangible machine components including a first party device, a data storage unit, a second party device, a computer, and a communications controller, programmed with specialized functions consistent with detailed algorithms disclosed in the patent, constitutes a patent ineligible “abstract idea;”

(2) “frightened” because, as Judge Moore puts it, “this case is the death of hundreds of thousands of patents, including all business method, financial system, and software patents as well as many computer implemented and telecommunications patents” (Moore Op. at 2); and

(3) “fantastical” because, as Judge Newman puts it, the en banc court was tasked to provide objective standards for 35 USC §101 patent-eligibility, but instead has “propounded at least three incompatible standards, devoid of consensus, serving to add to the unreliability and cost of the [patent] system…[such that] the only assurance is that any successful innovation is likely to be challenged in opportunistic litigation, whose result will depend on the random selection of the panel” (Newman Op. at 1-2).


Read More/続きを読む

Subscribe | 登録

Archives

Tags

词典 / 辞書 / 사전
  • dictionary
  • dictionary
  • 英語から日本語

Double click on any word on the page or type a word:

Powered by dictionarist.com